Tumor-infiltrating lymphocytes (TILs) have been reported as a prognostic factor in various cancers and are a promising target for immunotherapy. To investigate whether TILs have any impact on the prognosis of angiosarcoma patients, 55 non-treated patients (40 patients at stage 1 with cutaneous localized tumors, 4 patients at stage 2 with lymph node metastases and 11 patients at stage 3 with distant metastases) with angiosarcoma were evaluated retrospectively by immunohistochemistry stained CD4, CD8, FOXP3 and Ki67. The Kaplan-Meier method was used to estimate overall survival with patients at stage 1. Survival differences were analyzed by the log-rank test. Patients with higher numbers of CD8
and that the evaluation of tumor immunity may be possible by analyzing TILs.
Recent clinical experience in immunotherapy indicates that anti-tumor immunity mediated by T cells can have a strong impact on the clinical course of certain tumors. [5] [6] [7] Effective cancer immunotherapy is dependent on the presence of large numbers of anti-tumor lymphocytes with appropriate homing and effector functions that enable them to seek out and destroy cancer cells in vivo. 5 TILs have been reported as one of the representative manifestations of host anti-tumor immune response and as a target for immunotherapy. 5, 8, 9 Indeed, TILs are associated with the prognosis of various cancers. [10] [11] [12] [13] [14] [15] In addition, the analysis of T cell subsets in TILs can provide a deeper insight into anti-tumor immunity. In particular, CD8
1 effector T cells in TILs have associations with the prognosis of various cancers. 12, 14, [16] [17] [18] [19] [20] Conversely, the ratio of FOXP3 1 regulatory T cells (Tregs) in TILs is reported to have correlations with a worse prognosis in patients with certain cancers. 21, 22 Although tumor immunity can have an impact on the prognosis of angiosarcoma, the lymphocyte subsets of TILs and peripheral blood mononuclear cells (PBMC) in angiosarcoma patients have not been fully characterized. In this study, by means of immunohistochemistry, we have investigated whether the subsets of TILs have correlations with the clinical course or prognosis of patients with angiosarcoma. Moreover, to compare the frequencies of effector T cells in peripheral blood with healthy controls and other malignant cutaneous tumors, the percentage and IFN-g production of CD8
1 , CD4 1 T cells in PBMC of angiosarcoma, melanoma and healthy controls were assessed by flow cytometric analysis.
Material and Methods

Patient samples
Blood and tissue samples were obtained from Japanese patients with angiosarcoma (fresh blood samples n 5 10, paraffinembedded tissue samples n 5 55), healthy controls (fresh blood samples age-sex matched n 5 20) and melanoma patients (fresh blood samples, n 5 11). We retrospectively checked paraffin-embedded tissue samples (resected as biopsies or surgeries) and also medical records from Kyoto University Hospital, and found 29 patients with angiosarcoma from 1990 to 2012. In this article, we used tissues of non-treated primary cutaneous tumors. Thus, we excluded four samples, which had already received some treatment. We obtained 25 samples from the University of the Ryukyu, 2 samples from Fukui Red Cross Hospital and 3 samples from Kyoto City Hospital. Thus, we arrived at a total of 55 samples.
This study was approved by the Medical Ethics Committee of the Kyoto University Graduate School of Medicine, and was conducted in accordance with the principles of the Declaration of Helsinki. All patients and healthy controls provided written informed consent to participate in the study.
Patient's characteristics: clinical stages and the number of TILs
There had been no certain clinical tumor staging strategy for cutaneous angiosarcoma that reflected the prognosis or curative effect throughout the world. In this study, we classified our patients groups simply into three stages by modifying classic TNM classification as reported previously, stage 1 for those with cutaneous local tumors, 2 for those with lymph node metastases and 3 for those with distant metastases, 23, 24 which reflected the patients' prognosis. Our 55 non-treated patients (40 stage 1, 4 stage 2 and 11 stage 3 patients) with angiosarcoma were consistent with the previous report 23, 24 with the overall survival being different in each stage (Stage1-> 2 > 3) as estimated by the Kaplan-Meier method (data not shown for stage 2).
Non-treated primary tumor specimens of 55 patients were evaluated retrospectively by immunohistochemistry stained CD4, CD8, FOXP3 (n 5 55), MHC class1 (n 5 52), Ki67 (n 5 45) and CD31 (n 5 51). We performed Ki67 staining as a proliferation marker, calculating the Ki67-index of tumors, and using CD31 staining as a vascular endothelial cell marker to aid in the detection of tumors. Count data and patients' characteristics are presented in Table 1 .
Flow cytometric analysis
Flow cytometric analyses for PBMC of patients with untreated stage 1 angiosarcoma were planned and performed from 2007 to 2012 in Kyoto University Hospital. The total sample number was 10. PBMC were isolated with FicollIsopaque (Lymphoprep TM ; Axis-Shield, Oslo, Norway) gradient centrifugation. PBMC were freshly stained and analyzed with the following monoclonal antibodies as previously described 25 : allophycocyanin (APC) conjugated anti-CD4 (clone 11830; R and D systems); fluorescein isothiocyanate (FITC)-conjugated anti-IFN-g (clone 4S.B3; BD Biosciences); peridinin chlorophyll protein-Cy5.5 (PerCp-Cy5.5)-conjugated anti-CD8 (clone SK1; BD Biosciences).
What's new?
Tumor-infiltrating lymphocytes (TILs) have been reported to be a prognostic factor in various cancers. In this study, the authors investigated whether TILs have any impact on the prognosis of angiosarcoma. They found that higher numbers of CD8
1 TILs correlated with both a longer period free of distant metastases, and a more favourable prognosis. PBMC analysis showed that patients with angiosarcoma also had higher numbers of CD8 1 effector T cells than did healthy controls. TILbased immunotherapy may thus provide a promising approach to the treatment of angiosarcoma.
Tumor Immunology Acquisition and data analysis were performed with FACS Calibur (BD Biosciences) or LSR Fortessa (BD Biosciences) and Flow Jo software (Tree Star).
Intracellular cytokine staining
Fresh PBMC (5 3 10 6 cells/well) in 24-well plates were stimulated with 20 ng/ml PMA and 1 mM ionomycin in the presence of protein transport inhibitor monensin (Golgi-Stop, BD Biosciences) for 5 hr. Cells were harvested and co-stained with anti-CD4 and anti-CD8 monoclonal antibodies for surface staining. Then, cells were fixed, permeabilized with Cytofix/Cytoperm (BD Biosciences) and stained with anti-IFN-g monoclonal antibodies for intracellular staining prior to analysis by flow cytometry.
Immunohistochemistry
Tumor-infiltrating lymphocytes (TILs) were characterized in 3 mm-thick serial sections cut from formalin-fixed, paraffinembedded, tissue specimens of the most representative tumor areas. Immunohistochemistry by autoclave antigen retrieval methods was carried out as previously described. 26 The following primary anti-human monoclonal antibodies were used: anti-CD4 (clone 1F6; Novocastra, UK), anti-CD8 (clone C8/144B; Dako, Denmark), anti-FOXP3 (clone 236A/E7; eBioscience), anti-Ki67 (clone MM1; Novocastra, UK), anti-CD31 (clone 1A10; Novocastra, UK) and anti-MHC class1 (anti-HLA class I [HLA-A, B, C], clone EMR8-5, MBL Tokyo Japan).
Quantification of the tumor-infiltrating lymphocytes
In each immunostained serial section, the entire tumor area was evaluated for TILs at a scanning power (253 objective and 103 eyepiece). Areas with the most abundant TILs were selected, and a maximum of five randomly chosen high power field (HPF) (403 objective and 103 eyepiece) were digitally photographed and counted manually. The count was performed two times for each photograph by the same investigator (H.F.) without knowledge of earlier results. In all cases, absolute numbers of TILs (add CD4 1 T cell count and CD8 1 T cell count), CD4 1 T cell count) and CD8 / FOXP3 (CD8 1 T cell count divided by FOXP3 1 T cell count) were calculated. The average TILs count for each patient was used for statistical analysis. The Ki67-index was also calculated. All the immunohistochemical Ki67 stained glass slides were reviewed by our dermatopathologist (S.S.). The Ki67-index of tumor was defined as the percentage of tumor cells staining positive for the Ki67 antigen in the total number of tumor cells, by counting multiple regions with highest labeling density. To keep the index quality, we excluded bad Ki67 staining sections, in which it was difficult to distinguish tumor cells from surrounding connected tissues, or in which more than 500 tumor cells could not be counted.
Statistical analysis
Overall survival was measured as the time from the patient's first visit to the hospital to the time of death or the time the patient was last seen (until August 2012). For all immunohistochemical markers, cutoff for definition of subgroups was the median. The log-rank test was used to perform univariate analyses and the survival curves were estimated by the Kaplan-Meier method. The Mann-Whitney U-test was used for comparing unpaired flow cytometric data of two groups. The Kruskal-Wallis H-test was used for multiple comparisons. Correlations were evaluated using the Spearman's rank correlation coefficient. p values were two tailed and a p value < 0.05 was considered statistically significant.
Results
Prognostic significance of primary TILs in patients with stage 1 cutaneous angiosarcoma
To investigate whether the numbers of TILs and T cell subsets of TILs at cutaneous primary sites have a relationship with prognosis of patients with cutaneous angiosarcoma, immunohistochemical analysis of TILs of angiosarcoma was performed. Figure 1a shows the survival curve of our 40 non-treated stage 1 patients with angiosarcoma (Fig. 1a) . Immunohistochemical analysis of their primary tumors is done for CD31, Ki67, MHC class 1, CD4, CD8 and FOXP3 (Fig. 1b) . The patients with stage 1 cutaneous angiosarcoma were divided into two groups using the median value as the cutoff for each variable. The prognostic significance between the T cell subsets of TILs and their overall survival was calculated by the Kaplan-Meier method. Patients with higher numbers of CD8/HPF (high power field, high; n 5 20, low; n 5 20, p 5 0.019; Fig. 1c ) in their primary tumors demonstrated improved survival compared with patients with lower frequencies. No significant association was found for TILs/HPF (Fig. 1c) , CD4/HPF (Fig. 1c) , FOXP3/HPF (Fig. 1c) , ratio of CD8/CD4, FOXP3/CD4 (%FOXP3), CD8/FOXP3 of T cell subsets and Ki67-index of tumors (data not shown).
Next, to examine how the CD8 1 TILs contributed to the better prognosis of patients with angiosarcoma, we evaluated their disease-free survival. However, it was difficult for most patients to maintain tumor-free status because angiosarcoma spreads with unclear borders, so we could not clearly evaluate the disease-free survival. Clinical histories revealed that most patients with angiosarcoma died from lung metastases. Therefore, we chose to evaluate the relation between distant metastases (mainly lung) and TILs. Indeed, the periods between their initial visits to our hospital and distant metastases (distant metastasis-free period) were closely correlated with their overall survival (n 5 18, p 5 2.13E-06, r 5 0.874; data not shown). Moreover, CD8/HPF of TILs was positively correlated with the distant metastasis-free period (n 5 19, Figure 1 . Prognostic significance of primary TILs in patients with stage 1 cutaneous angiosarcoma. The survival curve of our 40 non-treated stage 1 patients with angiosarcoma (a). Representative immunohistochemistry was presented (b). The stage 1 patients were divided into two groups using the median value as the cutoff of each variable. The Kaplan-Meier method was used to estimate overall survival. Survival differences were analyzed by the log-rank test based on the number of TILs (CD8/HPF plus CD4/HPF), its subsets CD8/HPF, CD4/HPF and FOXP3/HPF (c). Correlation analysis was performed by Spearman rank correlation test with clinical parameters described below and frequencies of TILs. Primary TILs in stage 1 patients were used for the statistic. There was positive correlation between the months from initial visit to the hospital until patients developed distant metastases (in the graph, name as distant metastasis-free period) and the overall survival period of those patients who were deceased (n 5 18, data not shown). Correlation between distant metastasis-free period and the number of TILs (CD8/HPF plus CD4/HPF), its subsets CD8/HPF, CD4/HPF and FOXP3/HPF (c). p 5 0.0113, r 5 0.567; Fig. 1d) . No other immunohistological parameters had significant correlations with the distant metastasis-free period (Fig. 1d , and data not shown).
Significant correlation between primary TILs in stage 3 patients and overall survival Next, we evaluated correlation analysis with the prognosis of stage 3 patients who developed distant metastases, although we could not assess stage 2 patients who developed lymph node metastases because of the small number of patients. Figure 2a shows the survival curve of our 11 non-treated stage 3 patients with angiosarcoma (Fig. 2a) .
All 11 patients with stage 3 angiosarcoma had already died from the tumors. The number of primary TILs (CD4 plus CD8) and CD8
1 primary TILs of stage 3 patients was positively correlated with their overall survival (TILs; n 5 11, p 5 0.010, r 5 0.734, Fig. 2b, CD8 ; n 511, p 50.0314, r 5 0.647, Fig. 2b ).
The percentage of IFN-c production of CD8
1 T cells in
PBMC of patients with angiosarcoma
To evaluate whether T cells, especially CD8 effector T cells, are activated or differentiated in patients with angiosarcoma, we analyzed IFN-g production of CD4 1 and CD8 1 T cells in peripheral blood mononuclear cells (PBMC) using flow cytometry in available non-treated patients with cutaneous angiosarcoma (n 5 10, stage1) and compared it with healthy controls (HC, n 5 20) and patients with malignant melanoma (MM, n 5 11, stages 3 and 4) as a disease control.
The percentages of CD8 1 T cells producing IFN-g in PBMC were significantly higher in patients with angiosarcoma compared with those of healthy controls and patients with melanoma (IFN-g; median, HC 56.0% vs. AS 76.8% vs. MM 64.3%, p 5 0.0295 compared three groups by KruskalWallis H-test, AS > HC, p 5 0.0326, AS > MM p 5 0.0296 by Mann-Whitney U test. Fig. 3b) . Moreover, the percentage of IFN-g producing CD4
1 T cells was also significantly higher in angiosarcoma patients compared with those of healthy controls, but was not significant compared with those of melanoma patients (IFN-g; median, HC 12.8% vs. AS 23.7% vs. MM 16.5%, p 5 0.00992 compared three groups by KruskalWallis H-test, AS > HC, p 5 0.00324, AS > MM p 5 0.0884 by Mann-Whitney U test, Fig. 3b) .
These results indicated that PBMC in angiosarcoma patients contained significantly larger frequencies of CD8 1 
and CD4
1 effector T cells.
Discussion
To the best of our knowledge, this study provides the first immunological data showing that primary CD8 1 TILs are the most relevant T cell population in the prognosis of cutaneous angiosarcoma. Previous reports 2, 4 showed that higher numbers of TILs correlated with a favorable prognosis in patients with angiosarcoma. Our study examined immunological parameters of TILs including CD4, CD8, FOXP3 and found that CD8 is the most possible prognostic factor.
Galon et al. proposed a new cancer classification using "immunoscore," which is a tool including immunological biomarkers to predict prognosis and response to therapy. 27 The study stated that immunoscore should be incorporated into the traditional TNM classification. Our results indicated that tumor-infiltrated CD8 can be one parameter of the immunoscore in patients with angiosarcoma.
In our data, higher numbers of CD8 1 TILs resulted in a longer distant metastasis-free period. This result suggested that CD8
1 cytotoxic T lymphocytes in TILs are important in suppressing progression of angiosarcoma. It has been demonstrated in animal models that infiltration of tumors by tumor-reactive T lymphocytes is required for efficient tumor regression 28, 29 and the concentration of CD8 1 T cells determined the efficiency of target cell killing. 30 In human studies, accumulating evidence has shown that tumor infiltration by CD8 1 T cells is associated with a better prognosis in various cancers, such as bladder cancer, 12 renal cell carcinoma, 16 colorectal cancer, 14 ovarian cancer, 17, 18 esophageal carcinoma 19 and hepatocellular carcinoma. 20 CD8 1 cytotoxic T lymphocytes recognizing tumor antigens are also found in human melanoma-specific TILs, 31 and CD8 1 TILs cultured from metastatic melanoma exerted lytic activity on autologous melanoma cells. 31, 32 Therefore, tumor infiltrating CD8 1 T lymphocytes have been recognized to have antitumor effects on cancer patients. Together with our data, the contribution of CD8
1 TILs to the favorable prognosis in angiosarcoma seemed mostly due to the ability of CD8 1 T cells as tumor antigen-specific cytotoxic T lymphocytes to kill target cells directly, although the in vitro ionomycin assay evaluated in this study is only by PBMC and is not a conclusive experiment to prove the speculation.
To recognize a tumor, CD8 1 T cells need the expression of MHC class 1 on tumor cells. It was previously reported, through the analysis of a few cases, that angiosarcoma expressed both MHC class 1 and cancer-testis-antigen. 33 In this report, all the analyzed samples of angiosarcoma expressed MHC class 1 (n 5 52 data not shown). After recognition of a tumor, one of the mechanisms of tumor lysis by CD8 1 cytotoxic T lymphocytes is induced by Fas-ligand, and the expression of Fas-ligand in angiosarcoma by immunohistochemistry has also been previously reported. 4 Thus, direct recognition and lysis of tumors by CD8 1 cytotoxic T lymphocytes seem to be possible in our cases.
In addition, our PBMC analysis suggests that CD8 1 T cells are systemically activated and differentiated in most of the patients analyzed when compared with healthy controls and melanoma patients (Fig. 3b) , indicating that angiosarcoma patients had more CD8 1 cytotoxic T lymphocytes in PBMC. There is a possibility that anti-tumor immunity was activated in angiosarcoma and it seemed not to be immunosuppressive, although we have to highlight the limitations of the in vitro ionomycin assay.
Our data suggest that there might be certain tumor immunity against angiosarcoma and if we can activate CD8 1 TILs in the tumor-microenvironment and succeed in suppressing tumor growth locally, it might prevent tumor metastases and contribute to a favorable prognosis for patients with angiosarcoma. Furthermore, from our data, even if patients develop distant metastases, it still seems important that higher numbers of CD8
1 TILs at primary site contributed to their overall survival. There remains a strong possibility that immunological modification of TILs in the tumormicroenvironment may lead to new treatment strategies of angiosarcoma.
The tumor-infiltrating CD4 1 T cells and FOXP3 1 T cells were not significantly associated with the prognosis of patients with angiosarcoma in our data, even though suppression of anti-tumor immunity by Tregs is one of the important factors in tumor progression. 22 One possible explanation is that CD4 1 helper T cells have functionally different subsets such as T-helper 1 (Th1) cells, T-helper 2 (Th2) cells and immunosuppressive Tregs. Furthermore, all FOXP3-positive cells are not Tregs, 25 because FOXP3 1 T cells have functionally different subsets. These subsets have been shown to have opposite influences against tumor-immunity. The balances of these subsets are important for an anti-tumor effect. [34] [35] [36] In our data, the production of IFN-g in CD4 1 T cells (ascribed as Th1) significantly increased and percentages of elevated CD4 1 FOXP3 1 T cells (data not shown) in the peripheral blood of patients with angiosarcoma. Thus, there was a possibility that both anti-tumor Th1 and immunosuppressive Tregs were increased in the tumor microenvironment and were well-balanced.
Donghi et al. 37 reported that by analyzing nine patients with the Ki67-index of angiosarcoma, there was a tendency that the patients with the most unfavorable course showed a strong expression of Ki-67, while those with the best outcome only had a slight positive Ki-67 staining. The data from the 30-patient group we analyzed showed no statistically significant differences between the prognosis and Ki67-index of angiosarcoma, but there were tendencies that the groups with a lower Ki67-index had longer survival (data not shown). In this report, we could not include all the stained sections for Ki67-index count due to exclusion criteria. Thus, there is still a possibility that the Ki67-index of tumors is prognostically important for patients with angiosarcoma. Further investigation is required.
